Media coverage of the CCRCB (Wilson, McDade) led phase-I first in man trial of Lillys novel CDC7 inhibitor in p53 mutant cancers

Description

A number of articles covered the ccrcb led phase-I first in man trial of Lillys novel CDC7 inhibitor in p53 mutant cancers.  This trial is funded through a multi-centre CRUK New agents committee grant that was led by QUB Prof Richard Wilson (clinical lead), Simon McDade (Biology lead), Dan Longley, Richard Kennedy and Manuel Salot-Tellez